Background: MDA-9/syntenin and tissue factor (TF) are overexpressed in most types of human cancer. Results: Induction of MDA-9/syntenin in melanoma involves the binding of FVIIa and FX to TF on the cell surface, which initiates a signaling circuit essential for cell motility and metastasis of melanoma. Conclusion: MDA-9/syntenin is an important TF-regulated gene. Significance: Targeting TF-mediated MDA-9/syntenin may represent a novel therapeutic strategy for eliminating cancer.
Melanoma differentiation associated gene-9 (MDA-9), 2 also called syntenin, is a significant member of an expanding family of scaffolding PDZ domain-containing proteins, identified by a subtraction hybridization approach (1, 2) . MDA-9/syntenin contains a tandem repeat of PDZ domains that plays a central role in signaling pathways by organizing networks of receptors and in targeting selected cellular proteins to multiprotein complexes (2) (3) (4) . MDA-9/syntenin is up-regulated in a large spectrum of human malignancies, including melanoma (4 -7) . We previously documented that overexpressed MDA-9/syntenin acts through the Src pathway and initiates a signaling cascade that leads to activation of transcription factor NF-B and matrix metalloproteinases (MMP-2), which in turn promotes melanoma cell invasion/migration, and tumor cell metastasis in vivo (6, 8 -10) . However, it is unclear precisely how the change in extracellular environment influences MDA-9/syntenin gene expression that culminates in such a phenotype (11) .
It is now widely recognized that components of the blood cogulation cascade contribute to cancer development and progression (12) . Tissue factor (TF) is a transmembrane cellular receptor for coagulation factor VIIa (FVIIa) that orchestrates the assembly of FVIIa with substrate X, forming a ternary complex in which product Xa is generated (13) . The resulting TF⅐FVIIa⅐Xa efficiently activate a unique family of G proteincoupled receptors known as protease-activated receptors (PARs), in particular PAR-1 and PAR-2, thereby initiating the formation of a blot clot (14) . Besides its well documented role in hemostasis, TF is a promising metastasis-promoting gene that regulates multiple facets of tumor biology, including inflammation, cellular signaling, angiogenesis, tumor migration, and metastasis (15) . Similar to MDA-9/syntenin, TF is consistently overexpressed in several invasive tumors (16 -18) and is responsible for generation of active coagulant protease Xa (19) . A number of gain-and loss-of-function studies have shown that genetic modulation of TF promotes tumor cell invasion/migration and metastasis in vivo (20 -22) . Current studies indicate that the ternary TF⅐FVIIa⅐Xa complex, efficiently signals through PAR-1 or PAR-2 in a FXa-dependent manner (23, 24) and cross-talks with several important cellular signaling pathways, including MAPK pathway, Src family tyrosine kinases, and NFB members (25, 26) . Considering these many provocative findings, we have presently investigated the possible role of TF⅐FVIIa and the induced signaling pathways in regulation of MDA-9/syntenin expression.
We presently uncover a novel role of MDA-9/syntenin as an important TF⅐FVIIa⅐Xa-regulated gene that can initiate through PAR-1 a signaling circuit essential for cell motility, invasion, and metastasis of melanoma cells. These intriguing observations suggest that induction of MDA-9/syntenin could represent a key molecular event linking hemostasis and tumor progression. In these contexts, inhibition of TF⅐FVIIa⅐Xa and its relevant downstream targets such as MDA-9/syntenin, may be useful for managing thrombotic complications associated with malignancy but also for preventing tumor growth and dissemination.
MATERIALS AND METHODS
Reagents-Neutralizing anti-human tissue factor, anti-MDA-9, anti-HA tag antibody, anti-PAR-1 and anti-PAR-2, anti-Src, anti-p38, anti-MMP-2, anti-poly(A) polymerase (PAP) antibodies, and tissue factor, PAR-1, PAR-2, and PAP shRNAs lentiviral particles were purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA), anti-Rac1 and anti-Cdc42 (BD Biosciences Pharmingen, Franklin Lake, NJ), anti-paxillin Ser(P) 178 (BIOSOURCE International, Camarillo, CA). rFVIIa (NovoSeven) and FX were purchased from Novo Nordisk (Bagsvaerd, Denmark) and Hematologic Technologies (Essex Junctions, VT), respectively. FVIIa blocked in the active site with phenylalanyl-phenylalanyl-arginyl chloromethyl ketone (FFR-FVIIa/rFVIIai) was kindly provided by Dr. Lars C. Petersen (Novo Nordisk). Recombinant human TF (innovin) was obtained from Dade Behring (Deerfield, IL). Rivaroxaban was obtained from Bayer Healthcare (Leverkusen, Germany).
Cells, Transfection and Treatments-A primary normal human melanocytes (PromoCell, Heidelberg, Germany) were cultured according to the manufacturer's instructions. The poorly metastatic human melanoma cell line M4Beu and highly metastatic variants T1P26 and 7GP have been described (1) . Nonmetastatic radial growth phase primary melanoma cell line WM35 was purchased from Coriell Cell Repositories (Camden, NJ), and metastatic melanoma cell line c8161 was kindly provided by Dr. Mary Hendrix (Children's Memorial Research Center, Chicago, IL). Mycoplasma testing was carried out regularly using a polymerase chain reaction (PCR)-based methodology. The full-length human TF cDNA in pcDNA3.1 Hygro vector and the plasmid pcDNA HA-FAK were kindly provided by Lars C. Petersen (Novo Nordisk) and Kenneth Yamada (National Institutes of Health, Bethesda, MD), respectively. Standard methods were used to generate stable M4Beu cell lines expressing TF. Transient transfections of melanoma cells with HA-FAK were performed using Lipofectamine reagent as described (10) . Because FVII is equally present in plasma and serum (27) all of our studies were performed in cells grown in serum-free media to eliminate the unpredictable effect of factors present in the serum on the cellular responses of cell lines. When indicated, cells were incubated with various inhibitors before stimulation with agonists. Flow cytometry analysis was performed on a BD Biosciences FACSort flow cytometer.
Virus Construction and Infectivity Assays-Construction and characterization of Ad.MDA-9/AS (Ad expressing an antisense construct of MDA-9/syntenin), a dominant-negative (DN) kinase-deficient mutant p38 MAPK, c-Jun NH 2 -kinase (JNK), and mt32IB␣-superrepressor (Ad.IB␣-mt32) adenoviruses were prepared as described (6, 8) . Recombinant adenovirus expressing a DN mutant of c-Src kinase (K295R-kinase dead) was a generous gift from R. Baron (University School of Dentistry, Indianapolis, IN). Ad.DN⅐MEK1, Rac1, and CDC42 were from Cell Biolabs (San Diego, CA). Cells (2 ϫ 10 5 ) were infected either with the indicated adenovirus (6), or the lentiviral particles shRNAs for 2 h in DMEM according to the manufacturer's instructions (Santa Cruz Biotechnology). A stable melanoma cell line T1P26 with tissue factor silencing with shRNAs lentivirus expressing was generated according to the manufacturer's instruction (Santa Cruz). Luciferase assays were performed as described (8) . Forty-eight to 72 h post-transduction, cells were serum-starved and stimulated with the indicated agonists.
Reverse Transcription-PCR and Nuclear Run-on Assays-Reverse transcription-PCR was performed as described (8) . Two micrograms of total RNA isolated with the Qiagen RNeasy mini kit (Courtaboeuf, France) were used for reverse transcription-PCR using Superscript II reverse transcriptase (Invitrogen): MMP-2 sense, 5Ј-GTGCTGAAGGACACACTAAAGAAGA-3Ј; MMP-2 antisense, 5Ј-TTGCCATCCTTCTCAAAGTTGT-AGG-3Ј.
Nuclear Run-on Assays-Nuclear run-on assays were performed as described (28) . The in vitro elongation reaction was initiated with the addition of 0.25 mmol/liter each of ATP, GTP, CTP, and UTP for 25 min at 30°C. After incubation with RNase-free DNase, RNA was extracted and dissolved in water. cDNA was synthesized with the SuperScript III reverse transcriptase and amplified with Platinum Taq DNA polymerase (Invitrogen) using MDA-9/syntenin sense, 5Ј-GCTTGAACT-GTCGCCTTAAC-3Ј, and MDA-9/syntenin antisense, 5Ј-GACCATCCCAAAGTAGCTAG-3Ј as primers.
Protein Binding Assay-The full-length cDNA of MDA-9/ syntenin and ⌬PDZ(1 ϩ 2) (12) were inserted into pGEX-2T vector. The soluble glutathione S-transferase (GST) fusion proteins GST-MDA-9/syntenin and GST-⌬PDZ(1 ϩ 2) were expressed in Escherichia coli and purified by glutathione-Sepharose chromatography as described (29) . For the GST pull-down assay, 60 -100 g of GST-MDA-9/syntenin, GST-⌬PDZ(1 ϩ 2) or GST protein alone was incubated with glutathione-Sepharose 4B at 4°C for 2 h and then incubated with lysates for 4 h. The eluted proteins were subjected to Western blotting with the indicated antibodies. Active (GTP-bound) forms of RhoA, Rac1, or Cdc42 were captured by pulldown assay and quantified by Western blotting using anti-Rac and anti-Cdc42 antibodies (30) .
Immunoprecipitation and Western Blotting Analyses-Lysates of infected cells were prepared and equal amounts of proteins were electrophoresed, transferred, and probed with the indicated antibodies. Co-mmunoprecipitations were performed with the indicated antibodies or control IgG coupled to protein G-agarose (9) .
Zymography and ELISA-The activity of MMP-2 was determined by a QuickZyme activity assay kit (Quickzyme Biosciences, Netherlands). Briefly, after infection with the indicated virus, the cells were treated with agonists and medium was replaced with serum-free MEM. Sixteen hours later, the conditioned medium was collected, and MMP-2 activity in the super-natant was analyzed according to the manufacturer's instructions. The ELISA for MMP-2 were conducted with commercially available ELISA kits (R&D Systems, Minneapolis, MN).
FXa Generation Assay-FXa generation was quantified by reference to a standard curve constructed with recombinant human TF (31) . FXa in the supernatant was determined by addition of 25 mM of the chromogenic substrate PNAPEP25 and color development was measured at 405 nm on a microplate reader.
Cell Proliferation Assay-Measurement of cell proliferation based upon the reduction of the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) was used to assess cell viability. Briefly, cells were left untreated or infected with 50 pfu/cell of Ad.null or Ad.MDA-9/AS. 48 hours later, serum-starved cells were seeded in 96-well tissue culture plates (1.5 ϫ 10 3 cells/well) and treated with rFVIIa (10 nM) and FX (150 nM) for 60 min. At the indicated time points, the medium was removed, and fresh medium containing 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was added to each well. The cells were incubated at 37°C for 4 h and then an equal volume of solubilization solution (0.01NHCl in 10% SDS) was added to each well and mixed thoroughly. The optical density from the plates was read on a THERMO max microplate reader at 540 nm. All experiments were performed at least three times using quadruplicate samples. Data are presented as mean Ϯ S.E.
Cell Migration, Invasion, and Metastasis Assays-Cell invasion was determined as described (10) . Conditioned medium from NIH3T3 fibroblasts were added to the lower well in the presence of FVIIa ϩ FX and/or other agonists. For the migration assay, the lower wells were incubated with serum-free medium containing FVIIa ϩ FX and/or other agonists, and cell migration was followed over 18 h at 37°C (6) . Both assays were performed in the presence of recombinant hirudin (100 nM) to eliminate any effects of thrombin. The experimental metastasis assay was performed as described (8, 9) . Eight animals were used for each time point. Three weeks later, lung invasion was evaluated by counting pulmonary nodules under a dissecting microscope.
RESULTS

High Constitutive TF Expression Is Observed in Human Melanoma Cells
Overexpressing MDA-9/Syntenin-An anti-TF, monoclonal antibody (TF9 -10H10) showed that normal human melanocytes, a nonmetastatic radial growth phase primary melanoma cell line, WM35, and a weak metastatic human melanoma cell line, M4Beu, expressing low levels of MDA-9/ syntenin, contained also TF at very low levels ( Fig. 1A and Table  1 ). In contrast, the metastatic melanoma cells, T1P26, 7GP, and c8161 (expressing high levels of MDA-9/syntenin) showed a robust increase in TF protein expression compared with normal melanocytes, WM35 or M4Beu cells ( Fig. 1A and Table 1 ). Western blot analysis confirmed that TF is up-regulated in more aggressive melanoma cell lines ( Fig. 1B) and exhibited a Ͼ12-fold higher level of TF procoagulant activity when compared with normal melanocytes or poorly aggressive cell lines (Fig. 1C ). In total, these findings suggest that TF expressed on these metastatic cells is functionally active and its expression correlates with the expression levels of MDA-9/syntenin and the metastatic potential of melanoma cells.
Recombinant FVIIa and Xa Induces MDA-9/Syntenin Expression in Human Melanoma Cells-To test the hypothesis that FVIIa binding to TF in melanoma cells may regulate the expression of endogenous MDA-9/syntenin, serum-starved metastatic cell lines, T1P26, 7GP, and c8161 were treated with rFVIIa for 60 min. As shown in Fig. 1D expression of MDA-9/ syntenin was dose-dependently up-regulated by the addition of rFVIIa, which induces a very slight increase with 10 nM rFVIIa and a maximal response at 50 to 100 nM. In vivo, factor X zymogen binds to the TF⅐FVIIa complex (13), we determine whether rFVIIa was used at physiological plasma levels and combined with FX regulate MDA-9/syntenin expression. As anticipated, treatment of serum-starved metastatic cells with the combination of increasing concentrations of rFVIIa (0 -10 nM) and 150 nM FX induces a significant dose-dependent increase of MDA-9/syntenin producing a signaling response comparable with that observed with 50 nM rFVIIa ( Fig. 1E ). Time course experiments showed that the induction of MDA-9/syntenin was already observed as early as 30 min after initiation of the treatment and reached its maximum after 1 h compared with control cells (Fig. 1F ). As expected, addition of rFVIIa (10 nM) and FX (150 nM) to NHEM, or WM35 and M4Beu melanoma cells do not induce expression of MDA-9/syntenin in these cells (data not shown). We then generated a stable M4Beu cell line overexpressing TF (M4Beu/TF). M4Beu/TF cells were serum starved, and then treated with a combination of rFVIIa (0 -10 nM) and FX (150 nM) for 60 min. As shown in Fig. 1G , expression of MDA-9/syntenin was dose-dependently up-regulated following addition of rFVIIa and FX. These results suggest that at levels of rFVIIa that approach physiological concentrations, the ternary complex, TF⅐FVIIa⅐Xa, is a more potent inducer of MDA-9/syntenin expression than the binary complex in our melanocyte/melanoma model.
Inhibition of TF Signaling Prevents MDA-9/Syntenin Expression in Human Melanoma Cells-Active site-inactivated recombinant factor VIIa (rFVIIai) binds to TF but lacks catalytic activity; as such, it competes for TF with the physiologically occurring form of factor VIIa and is not capable of converting FX to its activated forms (32) . We then investigated whether rFVIIai could compete with rFVIIa for MDA-9/syntenin. As shown in Fig. 2A , inhibition of rFVIIa⅐Xa-induced MDA-9/syntenin expression in serum-starved metastatic cell lines T1P26, 7GP, and c8161 was dose-dependent and reached a maximum level of inhibition (ϳ90 -95% inhibition) with 100 nM rFVIIai compared with rFVIIa ϩ FX-treated cells. The level of MDA-9/syntenin protein in rFVIIa ϩ FX-stimulated melanoma cells was also inhibited by active site-directed factor Xa inhibitor (FXai), rivaroxaban (2 M), but not by hirudin (100 nM), a specific thrombin inhibitor ( Fig. 2B ). Additionally, after treatment of melanoma cells with anti-TF neutralizing antibody, a significant inhibition of rFVIIa⅐Xa-induced MDA-9/ syntenin expression was observed compared with control IgGtreated cells (Fig. 2C ). Furthermore, when TF shRNA lentiviral particles (LV-TF)-infected melanoma cells were exposed to rFVIIa ϩ FX, a substantial decrease of MDA-9/syntenin expression was evident at a multiplicity of infection of LV-TF as low as 1 and was maximal (ϳ90 -95% reduction) at doses of 20 m.o.i. when compared with a nonrelevant lentiviral control shRNA (LV-CTR) ( Fig. 2D ). In total, these findings employing rFVIIai, FXai, anti-TF antibody that block FX activation, and genetic approaches to block TF support the hypothesis that up-regulation of MDA-9/syntenin expression by tumor cells occurs through the TF⅐FVIIa⅐Xa pathway in malignant melanoma cells.
FVIIa⅐Xa-induced MDA-9/Syntenin Expression Signals through PAR-1 in Human Melanoma Cells-Because the ternary complex TF⅐FVIIa⅐Xa efficiently activates both PAR-1 and PAR-2 in a FXa-dependent manner (23, 24) , we first measured using flow cytometry expression levels of PAR-1 and PAR-2 in melanoma cells. All metastatic cell lines, T1P26, 7GP, and c8161, express high levels of PAR-1 and moderate levels of PAR-2 on their surface ( Fig. 2E and Table 2 ). Human melanocytes do not express PAR-1 and PAR-2 ( Fig. 2E and Table 2 ). These receptors were functionally active because both PAR-1 and PAR-2 peptide agonists increased intracellular Ca 2ϩ (data not shown).
We next determined the relative importance of the individual PARs in mediating MDA-9/syntenin expression. rFVIIa ϩ FX-induced MDA-9/syntenin expression was significantly decreased on infection of serum-starved metastatic cells, with PAR-1 shRNA lentiviral particles (LV-PAR-1, 20 m.o.i.) but not by LV-PAR-2 in comparison to cells infected with LV-CTR ( Fig.  2F ). The failure of hirudin to inhibit the TF⅐FVIIa⅐Xa-induced MDA-9/syntenin expression argues against thrombin as an intermediate on Xa signaling through PAR-1 (Fig. 2F ). In total, these findings employing genetic approaches to block PARs support the hypothesis that activation of PAR-1 is required for a TF⅐FVIIa⅐Xa-mediated increase in MDA-9/syntenin in malignant melanoma cells.
Factor VIIa and FX Increase MDA-9 mRNA Stability in Human Melanoma Cells-We next analyzed the molecular mechanisms by which rFVIIa and FX induce endogeneous MDA-9/ syntenin expression in melanoma cells. rFVIIa ϩ FX did not augment the promoter activity in melanoma cell lines beyond the basal activity and nuclear run-on assays substantiated the results obtained by promoter analysis (data not shown). Because FVIIa bound to TF up-regulates poly(A) polymerase (PAP), a known enzyme involved in mRNA translatability and stability that is activated in multiple tumors (33), we investigated the role of PAP in regulation of MDA-9/syntenin expression and stability. When serum-starved melanoma cells were treated with rFVIIa ϩ FX, the level of expression of PAP (M r ϳ 90,000) increased significantly compared with untreated cells (Fig. 2G ), whereas MDA-9/syntenin protein levels significantly decreased (ϳ90 -95% reduction) upon infection of these cells with LV-PAP compared with LV-CTR-infected cells (Fig. 2H ). In total, these results suggest that MDA-9/syntenin is regulated by a TF⅐FVIIa⅐Xa/PAR-1 signaling pathway at a post-transcriptional level, and that PAP promotes MDA-9/syntenin mRNA stability in malignant melanoma cells.
TF⅐FVIIa⅐Xa-induced MDA-9/Syntenin-mediated Signaling in Human Melanoma Cells-Experiments were performed to determine the intracellular signaling network underlying the TF⅐FVIIa-Xa-induced MDA-9/syntenin expression. Serumstarved rFVIIa ϩ FX-treated Ad.null-infected T1P26, 7GP, and c8161 cells caused substantial increases in the phosphorylation of c-Src, ERK1/2, p38, and JNK MAP kinase as compared with untreated cells ( 
TABLE 1 Surface expression of TF by flow cytometry analysis
Nonimmune mouse serum or anti-TF monoclonal antibody were incubated with normal human epidermal melanocytes (NHEM) or melanoma cells at different stages of tumor progression, and the binding reaction of antibodies to cells was analyzed as described under "Materials and Methods." Values represent the number of positive cells after background subtraction and are presented as mean Ϯ S.E. (n ϭ 3).
% Positively staining cells NHEM M4Beu WM35 7GP T1P26 c8161
Anti Because c-Src induces actin remodeling through activation of Cdc42 and Rac1 proteins (34) , and both can activate JNKs (35) , we investigated whether TF⅐FVIIa⅐Xa-induced MDA-9/ syntenin expression is involved in the activation of these two GTP-binding proteins. As apparent in Fig. 3B , the activity of Rho-like GTPases Cdc42 and Rac1 were significantly increased in rFVIIa ϩ FX-treated Ad.null-infected melanoma cell lines, T1P26 and c8161, compared with untreated cells (Fig. 3C) . In contrast, infection of melanoma cells with either Ad.MDA-9/AS or Ad.Src.DN (50 pfu/cell) significantly blocked FVIIa ϩ Tissue Factor FVIIa⅐FXa-induced MDA-9/Syntenin Expression FX-induced Rac1 and Cdc42 activity, when compared with untreated or rFVIIa ϩ FX-treated Ad.null-infected cells, respectively (Fig. 3B ). In total, these results suggest a signaling pathway consisting of c-Src-Cdc42-Rac1-JNK mediates TF⅐ FVIIa⅐Xa-induced MDA-9/syntenin expression in malignant melanoma cells.
Phosphorylation of paxillin, a focal adhesion-associated protein, was recently identified as a novel JNK substrate and can impact cell migration (36) . As expected, infection of metastatic cells, T1P26 and c8161, with either Ad.MDA-9/AS, Ad.Src.DN, or Ad.JNK.DN (50 pfu/cell) or Ad.Rac1.DNϩAd.Cdc42.DN (25 pfu/cell of each virus), induce a robust decrease in paxillin phosphorylation of Ser 178 compared with rFVIIa ϩ FX-stimulated Ad.null-infected cells (Fig. 3C) . Given that JNK can directly induce phosphorylation of paxillin on Ser 178 , which in turn increase the association of paxillin with FAK to facilitate the phosphorylation of paxillin on Tyr 31 and Tyr 118 during cell migration (36, 37) , we next considered whether rFVIIa⅐Xa-mediated MDA-9/syntenin expression was involved in the association of paxillin with FAK. Serum-starved melanoma cell lines c8161 and T1P26, transfected with HA-FAK, were stimulated with rFVIIa ϩ FX and cell lysates from these cells were then immunoprecipitated with HA antibody followed by immunoblotting with anti-phospho-Ser 178 , Tyr 31 , or Tyr 118 paxillin and FAK antibodies. As expected, phospho-Ser 178 , Tyr 31 , or Tyr 118 paxillin was found to associate with FAK in rFVIIa ϩ FX-stimulated melanoma cells, but such association was inhibited by Ad.Src.DN, with Ad.MDA-9/AS, Ad.Src.DN, or Ad.JNK.DN (50 pfu/cell) or Ad.Rac1.DN ϩ Ad.Cdc42.DN (25 pfu/cell of each virus), compared with rFVIIa ϩ FX-stimulated Ad.nullinfected cells ( Fig. 3D and data not shown) . Activation of the NF-B pathway is another key feature of TF⅐FVIIa⅐FXa-mediated regulation of gene expression (26) . Treatment of serumstarved melanoma cells, T1P26 and c8161, with rFVIIa ϩ FX significantly increased the transcriptional activity of the NF-B-responsive promoter compared with untreated cells (Fig. 4A) . In sharp contrast, the NF-B-responsive promoter was significantly decreased (up to 7-fold) on infection of melanoma cells with Ad.MDA-9/AS or Ad.Src.DN (50 pfu/cell) or Ad.Rac1.DN ϩ Ad.Cdc42.DN (25 pfu/cell of each virus), but not with Ad.JNK.DN compared with rFVIIa ϩ FX-treated Ad.null-infected cells (Fig. 4A ). We also determined whether TF⅐FVIIa⅐Xa-mediated expression of MDA-9/syntenin requires phosphorylation of the macromolecular IB kinase (IKK) complex, IB␣ and RelA/p65. As shown in Fig. 4B, rFVIIa ϩ FX increased the levels of phospho-Ser-IKK␣/␤, phospho-Ser-p65, and phospho-Ser-IB␣ in both c8161 and T1P26 melanoma cell lines. In sharp contrast, overexpression of MDA-9/AS or dominant-negative forms of Src or Rac1 and Cdc42 by means of adenoviral vectors (50, 50, and 25 pfu/cell of each virus, respectively) suppressed rFVIIa⅐Xa-induced phosphorylation of phospho-Ser-IKK␣/␤, phospho-Ser-p65, and phospho-Ser-IB␣ in melanoma cell lines, whereas adenovirus-mediated dominant-negative JNK (50 pfu/cell) has no effect ( Fig. 4B) . To confirm the functional end point of NF-B activation by TF⅐FVIIa⅐FXa-mediated MDA-9/syntenin expression, MMP-2, a well known NF-B target gene, was analyzed by RT-PCR and zymography. As expected, a significant increase in MMP-2 mRNA expression, MMP-2 protein levels, and active MMP-2 was detected in rFVIIa ϩ FX-stimulated metastatic cells, T1P26 and c8161, in comparison to untreated cells (Fig. 5, A and B) . In contrast, this increase in the levels of active MMP-2 expression was prevented (ϳ90 -95% reduction) following infection of melanoma cells with either Ad.MDA-9/AS or an adenovirus expressing the mt32IB␣ superrepressor (Ad.mt32Ib␣-mt32) (50 pfu/cell), which prevents p65 nuclear translocation when compared with rFVIIa ϩ FX-stimulated Ad.null-infected cells (Fig. 5, A and B) . As a corollary, treatment of rFVIIa ϩ FXstimulated metastatic cells with rivaroxaban, or LV-PAR-1 shRNAs significantly (ϳ85-95%) decreased activity of c-Src, Rac1, Cdc42, JNK, and paxillin in comparison with rFVIIa ϩ FX-treated LV-control shRNAs-infected cells (Fig. 5C ). Similarly, NF-B transcriptional activity and active MMP-2 was significantly decreased following infection of rFVIIa ϩ FX-stimulated melanoma cells with Ad.MDA-9/AS, LV-PAR-1 shRNAs, or treatment with rivaroxaban, compared with rFVIIa ϩ FXstimulated LV-control shRNAs-infected cells or rFVIIa ϩ FXstimulated Ad.null-infected cells (Fig. 5, D and E) . 
TABLE 2 Surface expression of PAR-1 and PAR-2 by flow cytometry analysis
Nonimmune mouse serum or specific monoclonal antibodies anti-PAR-1 or anti-PAR-2 were incubated with normal human epidermal melanocytes (NHEM) or melanoma cells at different stages of tumor progression, and the binding reaction of antibodies to cells was analyzed as described under "Materials and Methods." Values represent the number of positive cells after background subtraction and are presented as mean Ϯ S.E. (n ϭ 3).
% Positively staining cells
NHEM 7GP T1P26 c8161
Anti TF⅐FVIIa⅐Xa Promotes the Interaction of MDA-9/Syntenin with c-Src in Human Melanoma Cells-When overexpressed by means of an adenoviral expression system, MDA-9/syntenin associates with c-Src tyrosine kinase and initiates a signaling cascade that culminates in enhanced cell migration and invasion of melanoma cells (8) . rFVIIa ϩ FX induce a robust increase in MDA-9/syntenin protein expression and c-Src activity in melanoma cells. These findings prompted us to investigate whether interactions between MDA-9/syntenin and c-Src in melanoma cells are influenced by rFVIIa ϩ FX. Immunoprecipitation with anti-MDA-9 antibody pulls down a significant level of p-Src interacting with MDA-9/syntenin in rFVIIa ϩ FX-treated serum-starved metastatic cells, T1P26 and c8161, in comparison with control IgG antibody or untreated cells (Fig. 6A, left panel) . In contrast, this interaction was prevented in rFVIIa ϩ FX-treated cells that were infected with Ad.MDA-9/AS (50 pfu/cell), compared with control IgG or Ad.null-infected cells (Fig. 6A, right panel) . Double immunofluorescence also documented co-localization of c-Src and MDA-9 in rFVIIa ϩ FX-treated T1P26 and c8161 cells ( Fig. 6B and data not shown).
GST pulldown assay further verified the interaction between MDA-9/syntenin and p-Src in rFVIIa ϩ FX-stimulated melanoma cells. Physical interaction of MDA-9/syntenin and p-Src was significantly increased following incubation of rFVIIa ϩ FX-treated serum-starved lysates from T1P26 or c8161 melanoma cells in comparison with untreated cells (Fig. 6, C and D) . Additionally, GST-MDA-9/syntenin fusion proteins lacking both PDZ-1 and -2 domains (MDA-9⌬PDZ1 ϩ 2) failed to interact with endogeneous p-Src compared with full-length GST-MDA-9/syntenin in rFVIIa ϩ FX-stimulated tumor cells (Fig. 6, C and D) , providing further documentation of the in vivo interaction of MDA-9/syntenin with p-Src that requires exogeneous rFVIIa and FX.
Cell Migration, Invasion, and Metastasis of Human Melanoma Cell Depend on TF⅐FVIIa⅐Xa-mediated MDA-9/syntenin Expression-To assess further the involvement of TF⅐FVIIa⅐ FXa-induced MDA-9/syntenin expression in tumor cell migra- tion and invasion, two prominent characteristics of tumor malignancy, we first used in vitro cell migration and Matrigel invasion assays that were performed in the presence of hirudin.
As shown in Fig. 7, A and B, rFVIIa and 150 nM FX induce a significant dose-dependent increase of migration and invasion (ϳ4-to ϳ6-fold) of 7GP, T1P26, and c8161 cells, compared , and either untreated (UNT) or treated with active site-directed factor Xa inhibitor, rivaroxaban (RVX, 2 M), were exposed for 1 h with rFVIIa (10 nM) and FX (150 nM). A, total RNA was then extracted and RT-PCR was performed with primer pairs to amplify MMP-2 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The bar graphs represent densitometric results (mean Ϯ S.E.) from three or four independent experiments. B, the conditioned medium was then collected and processed by zymography as described under "Materials and Methods" (bottom panel). MMP-2 secretion from melanoma cells were determined by ELISA as indicated under "Materials and Methods" (lower panel). Each value represents the mean Ϯ S.D. (n ϭ 3). * and ࡗ, different from rFVIIa ϩ X-treated Ad.null-infected T1P26 and c8161 cells, respectively (p Ͻ 0.01), according to Student's t test analysis. C, cell lysates were subjected to SDS-PAGE and Western blot analysis with specific antibodies against phosphorylated c-Src, JNK, and paxillin, or to pulldown analysis of activated (GTP-bound) Rac1 and Cdc42. GTP-bound Rac1 and Cdc42 were affinity precipitated with a recombinant Pak1-CRIB and immunoblotted with anti-Rac1 and Cdc42 antibody as described under "Materials and Methods." Total paxillin, Rac1, and Cdc42 were detected with anti-paxillin, Rac1, and Cdc42 antibodies. The bar graphs represent densitometric results (mean Ϯ S.E.) from three or four independent experiments. D, NF-B promoter activity in melanoma cells. Twelve hours after infection, cells were transfected with a NF-B-responsive luciferase reporter construct. 48 -72 h after transfection, cells were serum-starved and treated with rFVIIa (10 nM) and FX (150 nM) for 60 min. Luciferase activity was measured as described under "Materials and Methods." Each value represents the mean Ϯ S.D. (n ϭ 3). *, different from rFVIIa ϩ X-treated cells (p Ͻ 0.01); ࡗ, different from rFVIIa ϩ X-treated LV-control-infected cells (p Ͻ 0.01); E, different from rFVIIa ϩ X-treated Ad.null-infected cells (p Ͻ 0.01); according to Student's t test analysis. E, MMP-2 secretion from melanoma cells. The conditioned medium was collected and MMP-2 secretion from melanoma cells was determined by ELISA as indicated under "Materials and Methods." Each value represents the mean Ϯ S.D. (n ϭ 3). *, different from rFVIIa ϩ X-treated LV-control-infected cells (p Ͻ 0.01); ࡗ, different from rFVIIa ϩ X-treated Ad.null-infected cells (p Ͻ 0.01); E, different from rFVIIa ϩ X-treated cells (p Ͻ 0.01); according to Student's t test analysis.
Tissue Factor FVIIa⅐FXa-induced MDA-9/Syntenin Expression
with rFVIIa alone. In contrast, adding rFVIIai (100 nM), rivaroxaban (2 M), neutralizing antibodies, along with rFVIIa and FX, markedly inhibited migration and invasion of melanoma cells, compared with rFVII ϩ FX-treated cells or IgG control antibody (Fig. 7, A and B) . More importantly, infection of rFVIIa ϩ FX-stimulated melanoma cells with LV-PAR-1 shRNAs (20 m.o.i.) or Ad.MDA-9/AS (50 pfu/cell) but not LV-PAR-2 also dramatically decreased (ϳ85-95%) cell migration and invasion, in comparison with rFVIIa ϩ FX-stimulated LVcontrol shRNA-infected cells, or rFVIIa ϩ FX-stimulated Ad.null-infected cells, respectively (Fig. 7, A and B) . This increased migration and invasion induced by rFVIIa ϩ FX was also strongly inhibited (ϳ85-90%) on infection of rFVIIa ϩ FX-stimulated melanoma cells with Ad.SrcDN, Ad.JNKDN, Ad.mt32Ib␣-mt32 (50 pfu/cell), or Ad.DNRac1 ϩ CDC42 (25 pfu/cell of each virus), compared with rFVIIa ϩ FX-stimulated Ad.null-infected cells (Fig. 8, A and B) . Despite the differences in the migratory and invasive potential of melanoma cell lines, cells treated with rFVIIa ϩ X in the presence or absence of adenoviral infection with Ad.MDA-9/AS (50 pfu/cell) did not show marked differences in their proliferation ( Fig. 9, A-C) . Because rFVIIa ϩ X induced MDA-9/syntenin expression in M4Beu/TF, we predicted that rFVIIa ϩ X would induce migration and invasion of M4Beu/TF cells. In agreement, increasing concentrations of rFVIIa (0.1, 1, and 10 nM) and 150 nM FX induce a significant dose-dependent increase of migration and invasion of melanoma cells overexpressing TF compared with rFVIIa alone (Fig. 7C) . In contrast, rFVIIai, rivaroxaban, anti-TF, or LV-PAR-1 shRNAs, or Ad.MDA-9/AS significantly altered M4Beu/TF cell migration and invasion compared with rFVIIa ϩ FX -stimulated Ad.null-infected cells or rFVIIa ϩ FX-stimulated LV-control shRNA-infected cells (Fig. 7C) . Additionally, infection of M4Beu/TF with Ad.SrcDN, Ad.JNKDN, Ad.mt32Ib␣-mt32, or Ad.DNRac1 ϩ CDC42, blocked migration and invasion of rFVIIa ϩ FX-stimulated M4Beu cells, compared with rFVIIa ϩ FX-stimulated Ad.nullinfected cells (Fig. 8C ). In total, these data further strengthen the involvement of the TF⅐FVIIa⅐FXa/PAR-1 signaling pathway in MDA-9/syntenin-induced migration and invasion of melanoma cells.
A direct involvement of FVIIa⅐TF-induced expression of MDA-9/syntenin in tumor cell metastasis was further evaluated in vivo. As demonstrated in Fig. 10A , the average number of metastatic lung lesions in untreated (146 Ϯ 8 and 150 Ϯ 10 lung nodules) or LV-control shRNA-infected cells, T1P26 and c8161 (152 Ϯ 10 and 148 Ϯ 8 lung nodules), was significantly decreased on infection of T1P26 and c8161 metastatic cells with shRNAs LV-TF (8 Ϯ 2 and 12 Ϯ 2 lung nodules). Similarly, the average number of lung metastatic foci was significantly increased in the MDA-9/syntenin group (86 Ϯ 12 lung nodules) and the TF group (98 Ϯ 10 lung nodules) compared with control M4Beu cells (12 Ϯ 2 lung nodules). In total, these in vitro and in vivo studies confirm a cause and effect relationship between TF-mediated MDA-9/syntenin expression and metastatic competence in human melanoma cells. 
DISCUSSION
We presently document, for the first time, that rFVIIa binding to tumor cell TF initiates a signaling cascade that culminates in the induction of MDA-9/syntenin leading to cell migration, invasion, and metastatic spread. Consistent with previous reports (23, 24, 38) , we found that rFVIIa, at a near plasma concentration (10 nM), is insufficient to induce MDA-9/syntenin expression in melanoma, and that FXa in the ternary TF⅐FVIIa⅐Xa complex efficiently induces expression of this gene in melanoma. We also document that a poly(A) polymerase, a TF-regulated gene that is up-regulated in multiple cancers in response to exposure to FVIIa (33) promotes MDA-9/ syntenin mRNA stability and translatability, thereby leading to an increase in melanoma cell motility and invasion. Importantly, we show that specifically blocking the functionality or expression of the pertinent signaling molecules can induce a signaling axis consisting of PAR-1/c-Src/Cdc42/Rac1/JNK/ paxillin and mediates TF⅐FVIIa⅐Xa-induced MDA-9/syntenin FIGURE 7. MDA-9/syntenin mediates cell migration and invasion of melanoma cells induced by rFVIIa and FX. A-C, serum-starved melanoma cell lines, 7GP, T1P26, and c8161 or M4Beu/TF were added to the upper well and rFVIIa ranging from 0.1 to 10 nM ϩ FX (150 nM) or rFVIIa (10 nM) ϩ FX (150 nM) were added to the lower well in the presence or absence of different agonists, including rFVIIai (100 nM), rivaroxaban (RVX, 5 M), or anti-TF antibody cH36 (100 g/ml) or a nonimmune mouse serum, in serum-free medium (migration). A and C, for invasion, FVIIa ϩ FX and other agonists were added to the lower wells that contained NIH3T3 cell-conditioned media (invasion by Matrigel invasion assay). B and C, in all cases, cells were infected with control shRNA, PAR-1, or PAR-2 shRNA lentiviral particles (LV-CTR, LV/PAR-1, and LV/PAR-2, 20 m.o.i), Ad.null or Ad-MDA-9/AS (50 pfu/cell), and analyzed for migration and invasion. Recombinant hirudin (100 nM) was added during invasion and migration assays to eliminate any effects of thrombin. The number of cells that migrated to the underside of the membrane after 18 -20 h incubation at 37°C or migrated across the Matrigel matrix to the underside of the membrane after a 48-h incubation at 37°C was determined. Columns, mean Ϯ S.D. (n ϭ 3). *, different from rFVIIa ϩ X-treated cells (p Ͻ 0,01); ϩ, different from rFVIIa ϩ X-treated control IgG cells (p Ͻ 0,01); double ϩ, different from rFVIIa ϩ X-treated LV-control-infected cells (p Ͻ 0,01); **, different from rFVIIa ϩ X-treated Ad.null-infected cells (p Ͻ 0.01); according to Student's t test analysis.
that leads to NF-B activation and subsequent expression of MMP-2, thereby promoting migration/invasion and metastatic potential of human melanoma cells.
Our findings provide strong evidence that PAR-1 is the central signaling receptor responsible for TF⅐FVIIa⅐FXa-induced MDA-9/syntenin in melanoma, as a reduction in PAR-1 pro- tein by siRNA significantly decreases melanoma cell migration/ invasion. These phenotypic changes did not involve thrombin formation suggesting that the promigratory and proinvasive roles of MDA-9/syntenin in melanoma resulted from the predominant activation of PAR-1 by FXa. It has been reported that PAR-1 and PAR-2 are complexed together and that cleaved PAR-1 transactivates PAR-2 to induce chemotaxis in multiple cancer cells (39, 40) . Interestingly, thrombin, but not FXa, activated the PAR-1⅐PAR-2 complex (39, 41) . Accordingly, it is conceivable that in our melanoma model increased expression of an important scaffolding protein, such as MDA-9/syntenin through a TF⅐FVIIa/PAR-1-dependent mechanism facilitates melanoma invasion and migration early in the metastatic process and subsequent activation of PAR-2 by the tethered ligand of cleaved PAR1, which has been described to contribute to thrombin responses in endothelial cells (41) , may allow tumor cells to acquire a highly aggressive phenotype. An intriguing question is how coagulation factors FVIIa and FX can orchestrate MDA-9/syntenin-induced tumor cell migration/invasion in extravascular space? Extravascular blood coagulation is observed in multiple cancers, including melanoma (42) . In preliminary studies, we were unable to detect FX mRNA expression in melanoma cells by RT-PCR. However, FX is frequently detected in several cancer specimens, including melanoma (18) , and may be locally delivered to the tumor microenvironment by macrophages/inflammatory cells that bind FX through Mac-1 (43) . These observations together with the fact that hypoxia in multiple cancers also enhances expression of FVII (44) , lend further support for a critical role of MDA-9/syntenin in the TF⅐FVIIa⅐Xa/PAR-1 signaling axis that regulates cell motility and tumor progression.
Multiple studies now indicate that TF⅐FVIIa⅐Xa complexes initiates signal transduction, resulting in the activation of a number of pathways that shape the microenvironment of the tumor (25, 26) . Interestingly, our results demonstrated that the PDZ scaffold protein MDA-9/syntenin forms a signaling complex with Src that requires exogeneous rFVIIa and FX. We observed that inhibition of the MDA-9/syntenin interactions with c-Src blocked TF⅐FVIIa⅐Xa/PAR-1-induced Rac-1/Cdc42 and JNK signaling and that inhibiting JNK prevented TF⅐ FVIIa⅐Xa/PAR-1-induced paxillin Ser 178 , and Tyr 31 /Tyr 118 phosphorylation. The JNK-SAPKs together with FAK have been shown to directly phosphorylate and regulate the activity of paxillin Ser 178 and Tyr 31 /Tyr 118 , three major JNK phosphorylation sites that facilitate tumor cell migration and metastatic spread of several human malignancies (36, 37, 45) . These observations coupled with our present findings suggest that the MDA-9⅐syntenin⅐c-Src signaling complex induced by a TF⅐ FVIIa⅐Xa pathway most likely facilitates tumor cells to leave their original tumor site and migrate to the lungs.
Several additional lines of evidence suggest that the MDA-9⅐syntenin⅐Src signaling complex is upstream of Rac-1 and Cdc42 and that these two different signaling molecules functionally cooperate with the TF⅐FVIIa⅐Xa-induced NF-B/ MMP-2 pathway to promote melanoma cell migration and invasion. Dominant-negative Rac-1 and Cdc42 mutants, but not JNK mutant, blocked NF-B activation induced by TF⅐FVIIa⅐Xa (Fig. 4A) , consistent with the observation that human Rac-1 and Cdc42 efficiently activate NF-B and JNK (46, 47) . Overall, these finding and our present study suggest a series of coordinated signaling transduction events involving MDA-9/syntenin that ultimately leads to the acquisition of a motile phenotype by melanoma cells. Indeed, blocking MDA-9/syntenin in response to rFVIIa and FX, or interfering with TF (48), Rho proteins (49), NF-B-regulated genes such as MMP-2 (50), or more importantly inhibition of the Src/paxillin signaling pathway (45, 51) has been shown to inhibit tumor growth and metastasis in preclinical studies and clinical trials.
In summary, we presently uncover a critical and hitherto unappreciated role of MDA-9/syntenin as an important TF⅐FVIIa⅐Xa/PAR-1-regulated gene that initiates a novel signaling circuit essential for cell motility, ECM invasion, and metastasis. Our findings support a hypothetical model whereby the ternary TF⅐FVIIa⅐Xa signaling complex acting through PAR-1 promotes expression and interaction of MDA-9/syn- FIGURE 9 . Effect of rFVIIa⅐Xa signaling on MDA-9/syntenin-induced cell proliferation of melanoma. A-C, cells were left untreated (UNR) or infected with 50 pfu/cell of Ad.null or Ad.MDA-9/AS. 48 h later, serum-starved cells were seeded in 96-well tissue culture plates (1.5 ϫ 10 3 cells/well) and treated with rFVIIa (10 nM) and FX (150 nM) for 60 min. At the indicated time points, the medium was removed, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each well as indicated under "Materials and Methods." The optical density from the plates was read on a THERMO max microplate reader at 540 nm. All experiments were performed at least three times using quadruplicate sample. Data are presented as mean Ϯ S.E. tenin with c-Src, which then activates the Rho GTPases, Rac/ Cdc42-mediated NF-B activation, and JNK-mediated paxillin phosphorylation through two distinct signal transduction pathways leading to enhanced cell motility, invasion, and metastasis (Fig. 10B ). The link established in this study between the TF signaling complex and MDA-9/syntenin has significant implications for the regulation of motility events associated with wound healing and tumor metastasis because PAR-1 has protumorigenic and pro-metastatic effects on cancer cells (52, 53) . In these contexts, up-regulation of an important PDZ scaffolding signaling protein, such as MDA-9/syntenin, through a TFdependent mechanism, with the ability to recruit and organize formation of the TF signaling complexes may significantly affect melanoma progression and potentially progression of other malignant tumors. Therapeutics that prevent TF⅐FVIIa⅐Xa complex formation and its regulated genes may be useful for managing thrombotic complications associated with malignancy but also for preventing tumor growth and dissemination.
